Treatment of hepatocellular carcinoma: too many options?
about
Melanoma differentiation-associated gene-7, MDA-7/IL-24, selectively induces growth suppression, apoptosis in human hepatocellular carcinoma cell line HepG2 by replication-incompetent adenovirus vector.Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients.T(2) relaxation times of (13)C metabolites in a rat hepatocellular carcinoma model measured in vivo using (13)C-MRS of hyperpolarized [1-(13)C]pyruvate.Diphenyl difluoroketone: a potent chemotherapy candidate for human hepatocellular carcinomaNon-surgical treatment of hepatocellular carcinoma.Early experience of helical tomotherapy for hepatobiliary radiotherapyThalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis(188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside.NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgeryImmunotherapy of cancer in 2012.Drug testing and flow cytometry analysis on a large number of uniform sized tumor spheroids using a microfluidic deviceProspective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinomaAFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway.A combination therapy of ethanol injection and radiofrequency ablation under general anesthesia for the treatment of hepatocellular carcinomaImpaired liver function attenuates liver regeneration and hypertrophy after portal vein embolization.Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.Ultrasound-targeted HSVtk and Timp3 gene delivery for synergistically enhanced antitumor effects in hepatoma.In vivo bioluminescent imaging of α-fetoprotein-producing hepatocellular carcinoma in the diethylnitrosamine-treated mouse using recombinant adenoviral vector.Membrane-bound form of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy in a model of hepatocellular carcinoma.Suicidal gene therapy in the effective control of primary human hepatocellular carcinoma as monitored by noninvasive bioimaging.Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma.HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity.Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma.Effect of preoperative radiological treatment of hepatocellular carcinoma before liver transplantation: a retrospective study.Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma.Complete cure of established murine hepatocellular carcinoma is achievable by repeated injections of retroviruses carrying the herpes simplex virus thymidine kinase gene.A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds.Cryosurgery as a treatment for advanced stage hepatocellular carcinoma: results, complications, and alcohol ablation.Hepatocellular carcinoma
P2860
Q33238647-E5B4D3F2-8E8A-4BFE-B9AD-3BC0960ABC6AQ33333673-856C3F10-B521-4797-B502-25E6FAF6F628Q33503017-80A9D941-942C-4C7F-AF44-ECDF66768C1BQ33937080-EEAC3AA0-CE45-4386-9A7A-B21F5DD9EE95Q34013776-EDC3B4D4-83B7-4E29-B3BA-6E2427BB4244Q34539241-994A76A3-8384-44D8-9391-7DDD90F42A6CQ35545055-F647F95B-BF39-4E9C-BC19-0F62F11C1D46Q35725800-FEFEBA96-9A76-41D9-9064-5765C871332AQ35821571-0D3BD556-7417-4A96-8B1D-387BE032FE36Q35995828-089AA580-1614-4D4F-8E48-A8C668B0AF3FQ36243536-7D3A4791-D9BB-4D60-8009-45A9FA2DB855Q36579534-20BD8947-695E-4207-B02B-73CDDD672059Q36671639-25B68878-DD2F-432B-AE5B-2A9A0201ACC9Q36673674-7B9D98E4-40F4-4907-9D84-0924746F705BQ36730357-861A7EF9-4147-4924-BE4D-01B9882D4496Q36774942-EC0FAB2D-2D73-46DA-91FA-716C01FC61F5Q37240393-4C1D6D59-5CC8-4D3A-83D8-E2385C991ACAQ37321973-38F9E8BE-4A0A-4D5B-A343-E518C71CD24EQ38113503-C862BC17-71F3-4AC4-8C73-763D476D28BDQ39163973-3A0F8680-3876-4D2B-8A42-D6101FB3D441Q39320280-0D120D5C-8034-4D9C-9143-A20D666BA32CQ39382979-51FC914A-D8B1-419D-9249-C572F43B7397Q39473687-C9186157-84FD-4C40-BA68-482A9F3771CAQ40586640-F7F14881-8EEF-40D4-AA76-05F68E831633Q43921056-EC60AE12-372B-4FF8-98C1-3F618EB3F611Q44393120-C99EA59F-E5DA-4C6D-8B73-EDE54F98C679Q44577708-26901B98-C5F8-465B-AB6B-63FB973EB85BQ45746250-BE0AE3F5-F91C-4205-866B-C01ECFB00A0CQ45747425-2AC76805-A089-4107-AB61-27F6F991501EQ45872992-396FB5A2-0163-48D7-88B5-2E4E772F5C73Q46089063-693C57B5-C6CE-4C12-923C-6CAEEC58815CQ57757274-3E4DD303-BA0E-4943-92A7-1C14FDFC570E
P2860
Treatment of hepatocellular carcinoma: too many options?
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Treatment of hepatocellular carcinoma: too many options?
@en
type
label
Treatment of hepatocellular carcinoma: too many options?
@en
prefLabel
Treatment of hepatocellular carcinoma: too many options?
@en
P1476
Treatment of hepatocellular carcinoma: too many options?
@en
P2093
A P Venook
P304
P356
10.1200/JCO.1994.12.6.1323
P407
P577
1994-06-01T00:00:00Z